Ridgeland, Mississippi 39157

  • Migraine

Purpose:

The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.


Criteria:

Inclusion Criteria: - Have a diagnosis of migraine per International Headache Society (IHS) International Classification of Headache Disorder (ICHD)-3 guidelines at least 12 months prior to screening. - Have a history of ≥ 8 migraine days/month in 2 of the previous 3 months as confirmed by the treating physician through medical records. - Be able to understand the clinical description of treatment options and have the capability to participate fully in making their treatment preferences known. - Be willing to accept randomization to any of the possible study medications if allocated to that treatment arm. - Be willing and capable of completing daily reports and other participant reported outcome measures using a smartphone-based application. Exclusion Criteria: - The participant has a history of severe drug allergy or hypersensitivity, or known hypersensitivity or intolerance to either eptinezumab, erenumab, fremanezumab, galcanezumab or their excipients. - The participant has previous history of use of any of the study drugs (for example, eptinezumab, Botox, erenumab, fremanezumab or galcanezumab). Note that only previous Botox use for treatment of migraine is exclusionary. Prior use of Botox for cosmetic purposes is allowed. - The participant has a diagnosis of CM and has hypersensitivity to botulinum toxin preparation or to any of the components in the formulation. - The participant has used opioids or butalbital-containing products greater than 4 days per month in the last month. Other inclusion and exclusion criteria may apply.


NCT ID:

NCT05284019


Primary Contact:

Study Director
Email contact via H. Lundbeck A/S
LundbeckClinicalTrials@Lundbeck.com

Email contact via H. Lundbeck A/S
Phone: +45 36301311
Email: LundbeckClinicalTrials@Lundbeck.com


Backup Contact:

N/A


Location Contact:

Ridgeland, Mississippi 39157
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 02, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.